RT Journal Article
SR Electronic
T1 Prognostic Significance of Peripheral Blood CD8<em><sup>high</sup></em>CD57<em><sup>+</sup></em> Lymphocytes in Bladder Carcinoma Patients After Intravesical IL-2
JF Anticancer Research
JO Anticancer Res
FD International Institute of Anticancer Research
SP 699
OP 703
VO 31
IS 2
A1 CHARACIEJUS, DAINIUS
A1 PAŠUKONIENĖ, VITA
A1 JACOBS, JOHN J.L.
A1 EIDUKEVIČIUS, RIMANTAS
A1 JANKEVIČIUS, FELIKSAS
A1 DOBROVOLSKIENĖ, NERINGA
A1 MAURICAS, MYKOLAS
A1 VAN MOORSELAAR, R. JEROEN A.
A1 DEN OTTER, WILLEM
YR 2011
UL http://ar.iiarjournals.org/content/31/2/699.abstract
AB Background: The objective of this study was to evaluate the recurrence-preventing effect of intravesical instillations of interleukin-2 (IL-2) in patients with non-muscle-invasive bladder carcinoma. In addition, this study aimed to determine the significance of immune parameters for recurrence-free interval. Patients and Methods: Twenty-six patients with non-muscle-invasive bladder carcinoma were treated with intravesical instillations of IL-2 (Proleukin®, Novartis, formerly Chiron) in doses of 9×106 IU on 5 consecutive days, beginning on the second day after transurethral resection (TUR) of tumours. CD8highCD57+ lymphocytes in peripheral blood were determined before TUR and compared with the recurrence-free interval after treatment. Results: The multivariate analysis showed that CD8highCD57+ lymphocytes had a prognostic significance in combination with number of bladder tumours, prior recurrence rate and age of patients. Conclusion: Peripheral blood CD8highCD57+ lymphocytes have prognostic significance for recurrence-free survival in patients with non-muscle-invasive bladder carcinoma after TUR and intravesical IL-2.